265 related articles for article (PubMed ID: 37543051)
1. A systematic review of cannabidiol trials in neurodevelopmental disorders.
Parrella NF; Hill AT; Enticott PG; Barhoun P; Bower IS; Ford TC
Pharmacol Biochem Behav; 2023 Sep; 230():173607. PubMed ID: 37543051
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Black N; Stockings E; Campbell G; Tran LT; Zagic D; Hall WD; Farrell M; Degenhardt L
Lancet Psychiatry; 2019 Dec; 6(12):995-1010. PubMed ID: 31672337
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
Cannabis Cannabinoid Res; 2024 Feb; 9(1):230-240. PubMed ID: 35881851
[No Abstract] [Full Text] [Related]
4. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry.
Bellocchio L; Patano A; Inchingolo AD; Inchingolo F; Dipalma G; Isacco CG; de Ruvo E; Rapone B; Mancini A; Lorusso F; Scarano A; Malcangi G; Inchingolo AM
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298644
[TBL] [Abstract][Full Text] [Related]
7. Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies.
Daldegan-Bueno D; Maia LO; Glass M; Jutras-Aswad D; Fischer B
Eur Neuropsychopharmacol; 2021 Oct; 51():106-131. PubMed ID: 34273801
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.
Hindley G; Beck K; Borgan F; Ginestet CE; McCutcheon R; Kleinloog D; Ganesh S; Radhakrishnan R; D'Souza DC; Howes OD
Lancet Psychiatry; 2020 Apr; 7(4):344-353. PubMed ID: 32197092
[TBL] [Abstract][Full Text] [Related]
9. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of Δ
Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
[TBL] [Abstract][Full Text] [Related]
11. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
12. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
13. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.
Freeman TP; Craft S; Wilson J; Stylianou S; ElSohly M; Di Forti M; Lynskey MT
Addiction; 2021 May; 116(5):1000-1010. PubMed ID: 33160291
[TBL] [Abstract][Full Text] [Related]
14. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder.
Hua DY; Hindocha C; Baio G; Lees R; Shaban N; Morgan CJ; Mofeez A; Curran HV; Freeman TP
Transl Psychiatry; 2023 Apr; 13(1):131. PubMed ID: 37085531
[TBL] [Abstract][Full Text] [Related]
15. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
16.
Canseco-Alba A; Rodríguez-Manzo G
Rev Invest Clin; 2023; 75(3):105-128. PubMed ID: 37441766
[TBL] [Abstract][Full Text] [Related]
17. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids for the treatment of dementia.
Bosnjak Kuharic D; Markovic D; Brkovic T; Jeric Kegalj M; Rubic Z; Vuica Vukasovic A; Jeroncic A; Puljak L
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012820. PubMed ID: 34532852
[TBL] [Abstract][Full Text] [Related]
19. Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.
Ganesh S; Cortes-Briones J; Schnakenberg Martin AM; Skosnik PD; D'Souza DC; Ranganathan M
Cannabis Cannabinoid Res; 2023 Oct; 8(5):846-856. PubMed ID: 35319274
[No Abstract] [Full Text] [Related]
20. Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations.
Espinosa-Jovel C
Neurologia (Engl Ed); 2023; 38(1):47-53. PubMed ID: 34824031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
